We at peHUB have written about emerging biofuels companies on a number of occasions in the past year, chronicling the rush of these still formative companies to the IPO window. Here is a useful “cheat sheet” courtesy of Lux Research on who the ultimate winners and losers could be. The biofuels and biochemical industries are [...]
You are browsing the archive for Codexis - peHUB.
Codexis Inc., a Redwood City, Calif.-based provider of solutions for pharma chemical process development and manufacturing, raised around $78 million via its IPO. The company priced six million shares being offered at $13 per share, or the low end of its $13-$15 per share range. The company’s initial market cap is approximately $441 million. It will trade on [...]
Codexis Inc., a Redwood City, Calif.-based provider of solutions for pharma chemical process development and manufacturing, has set its IPO terms to six million shares being offered at between $13 and $15 per share. The company would have an initial market cap of nearly $509 million, were it to price at the high end of its [...]
NEW YORK (Reuters) – U.S. biotechnology company Codexis Inc filed for an initial public offering of up to $100 million on Monday. The company provides enzymes and microbes that make industrial processes cleaner and faster. Its pharmaceutical products are used by drugmakers including Merck & Co Inc (MRK.N), Pfizer Inc (PFE.N) and Dr Reddy’s Laboratories [...]
SAN FRANCISCO (Reuters) – U.S. biotechnology company Codexis, which is partly owned by Royal Dutch Shell Plc, is expanding its product offerings to target the emerging market for carbon capture and storage, President and Chief Executive Officer Alan Shaw said on Tuesday. Coal-fired power plants provide about half of the electricity in United States, but [...]
Royal Dutch Shell has increased its equity stake in Codexis Inc., a developer of industrial biocatalysts, including enzymes and microbes. No financial terms were disclosed for the deal, which was part of a larger strategic arrangement. Codexis last year canceled plans for a $100 million IPO. At the time, it had raised over $80 million from CCTV Investments, CMEA Ventures, Pequot Capital, Pfizer, Maxygen and Bio*One Capital.
Codexis Inc., a Redwood City, Calif.-based provider of solutions for pharma chemical process development and manufacturing, has withdrawn registration for a $100 million IPO. It has planned to trade on the Nasdaq, with Credit Suisse and Goldman Sachs serving as co-lead underwriters. Codexis has raised just over $80 million in VC funding since 2002, from [...]